Cannabidiol-Enriched Extract Oil for Postoperative Management of Chronic Pelvic Pain Secondary to Endometriosis: A Randomized Clinical Trial-DREAMLAND Study

Gabrielle Barbosa Anelli, Anelli GB, Ratochinski R, R. H. Ratochinski, Rodrigo Ratochinski, Igor Gustavo Carvalho Oliveira, Igor Gustavo de Carvalho Oliveira, Oliveira IGC, Souza ID, Israel Donizeti de Souza, Israel Donizéti de Souza, Maria Eugênia Queiroz Nassur, Maria Eugênia Costa Queiroz, Nassur MEQ, FJ Candido‐dos‐Reis, Candido-Dos-Reis FJ, Francisco José Candido-Dos-Reis, Zuardi AW, Antonio Waldo Zuardi, Antônio Waldo Zuardi, Junior WM, Wilson Marques Junior, Rosa-E-Silva JC, Júlio César Rosa-e-Silva, Jaime Eduardo Cecílio Hallak, Hallak JEC, Crippa JAS, José Alexandre S. Crippa, José Alexandre de Souza Crippa, Poli-Neto OB, Omero Benedicto Poli‐Neto, Omero Benedicto Poli-Neto
Cannabis and cannabinoid research · 2026 · pp. 25785125251413989 · doi:10.1177/25785125251413989 · PMID:42261989 · W7123804101
article OA: closed CC0
Full text JSON View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by claude@2026-06, 2026-06-06 ⓘ

This randomized trial found that cannabidiol-enriched oil was not superior to placebo in reducing postoperative chronic pelvic pain in women with endometriosis, despite some improvements in psychological symptoms and quality of life.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

INTRODUCTION: Retrospective studies and patient surveys investigating cannabis-based products for endometriosis have suggested potential benefits, highlighting the unmet need for effective therapeutic alternatives. This study evaluated the efficacy of cannabidiol in reducing pain among women with surgically treated endometriosis who experienced symptom recurrence. MATERIALS AND METHODS: This was a single-centre, randomised, parallel, triple-blind, placebo-controlled trial. Eligible participants were women with surgically confirmed endometriosis, previously treated surgically, receiving hormonal therapy, and reporting symptom recurrence. A total of 102 participants were randomized (1:1) into two groups, with 51 allocated to oral cannabidiol-enriched oil (CBDO) and 51 allocated to placebo. The intervention lasted 10 weeks. The oil was administered twice daily with dose escalation from 10 mg/day (week 1) to 150 mg/day (week 9), followed by tapering. The study was terminated after the planned interim analysis due to a lack of difference in the primary outcome and a higher frequency of adverse events in the CBDO group. Primary outcomes were changes in pain intensity (Visual Analogue Scale) and the proportion of participants with ≥30% and ≥50% pain reduction. Participants reported their average perceived pain intensity during the preceding week at each visit. Secondary outcomes included sensory thresholds, psychiatric symptoms, functional impairment, quality of life (QoL), and adverse effects, focusing on common cannabidiol-related symptoms. RESULTS: Approximately 40% of participants in both groups achieved ≥50% pain reduction, and ∼60% reported ≥30% improvement. At the end of treatment, mean pain intensity was 41.6 mm in the CBDO group and 36.8 mm in the placebo group. Although both groups showed significant within-group reductions, differences between groups were not significant. CBDO was associated with improvements in psychological symptoms and several QoL domains but also with more mild adverse events, mainly gastrointestinal symptoms and perceived weight changes. Participants in the placebo group exhibited better scores in physical QoL domains. No serious adverse events occurred. DISCUSSION: Both groups showed consistent and significant pain reduction, but cannabidiol was not superior to placebo. The trial was discontinued at the interim analysis due to the absence of clinically relevant benefit and higher mild adverse-event rates with CBDO. Improvements in placebo-treated participants highlight potential placebo effects and the limited power of secondary analyses.
Full text 1,456 characters · extracted from oa-doi-fallback · 5 sections · click to expand

Abstract

Introduction:

Materials and methods

Results:

Discussion

Get full access to this article View all access and purchase options for this article. Data availability statement Attestation Statement

References

Cite Cite Cite Download to reference manager If you have citation software installed, you can download citation data to the citation manager of your choice Information, rights and permissions Information Published In

Keywords

Data availability statement Authors Metrics and citations Metrics Journals metrics This article was published in Cannabis & Cannabinoid Research. View All Journal MetricsPublication usage* Total views and downloads: 838 *Publication usage tracking started in December 2016 Publications citing this one Receive email alerts when this publication is cited Web of Science: 0 Crossref: There are no citing articles to show. Figures and tables Figures & Media Tables View Options Access options If you have access to journal content via a personal subscription, university, library, employer or society, select from the options below: loading institutional access options Alternatively, view purchase options below: Purchase 24 hour online access to view and download content. Access journal content via a DeepDyve subscription or find out more about this option.

Text is read by the "Ask this paper" AI Q&A widget below. Extraction quality varies by source — PMC NXML preserves structure cleanly, OA-HTML may include some navigation residue, and OA-PDF can have broken hyphenation. The publisher copy (via DOI) is the canonical version.

My notes (saved in your browser only)

⚙ Ask this paper AI returns verbatim quotes from the full text · source: oa-doi-fallback ⓘ

Answers must be backed by verbatim quotes from this paper's full text. Hallucinated quotes are dropped automatically; if no verbatim passage answers the question, we say so. How this works

Condition tags

endometriosischronic_pelvic_pain

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (83)

Cited by (1)

SciLite annotations

chemicals 5
cannabidiol cannabidiol cannabidiol cannabidiol cannabidiol
organisms 1
cannabis

Source provenance

europepmc
last seen: 2026-07-27T06:15:28.040536+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-07-27T06:09:29.080095+00:00
scilite
last seen: 2026-07-12T09:48:33.364277+00:00
License: CC0 · commercial use OK